argenx (NASDAQ:ARGX) said its Phase 2 study of FB102 in adults with celiac disease met its primary endpoint, showing a statistically significant improvement versus placebo at day 78 with a p-value of 0.0176.
argenx (NASDAQ:ARGX) will discontinue its Phase 3 UNITY study of subcutaneous efgartigimod in adults with moderate-to-severe Sjögren's disease after an interim analysis found the trial could not meet its primary endpoint.
Cosmos Health (NASDAQ:COSM) reported preliminary nine-month revenue of approximately $54.3 million for the period ended September 30, 2026.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) announced positive preclinical results for its Bisphosphocin compounds in animal models of urinary tract and pulmonary infections.
AbbVie (NYSE:ABBV) received two FDA Breakthrough Therapy Designations for its investigational asset, telisotuzumab adizutecan (Temab-A).
BD (NYSE:BDX) announced nine-month AGILITY trial results showing its Revello Vascular Covered Stent met the primary endpoint with a 97.2% primary patency rate in iliac artery disease.
Cadrenal Therapeutics (NASDAQ:CVKD) initiated a formal strategic review process and retained Tungsten Advisors as its exclusive financial advisor.
Seaport Therapeutics (NASDAQ:SPTX) dosed the first patient in its Phase 2a clinical trial in Australia evaluating GlyphAgo in adults with generalized anxiety disorder and sleep disturbance.
Nurix Therapeutics (NASDAQ:NRIX) enrolled the first patient in its Phase 1b/2 clinical study combining bexobrutideg with venetoclax for the treatment of chronic lymphocytic leukemia.
Oculis (NASDAQ:OCS) will present its investigational dry eye treatment, Licaminlimab, at the Eyecelerator @ AAO 2026 conference on October 8.
Esperion Therapeutics (NASDAQ:ESPR) entered into a settlement agreement with Renata and an affiliate resolving patent litigation concerning proposed generic versions of NEXLETOL and NEXLIZET in the United States.
Quantum BioPharma (NASDAQ:QNTM) signed a study agreement with Thermo Fisher Scientific (NYSE:TMO) to implement its Phase 2 trial.
